Get the Stockscreener App
49.08
2.29%
-1.15
Bridgebio Pharma Inc stock is traded at $49.08, with a volume of 1.49M.
It is down -2.29% in the last 24 hours and up +7.23% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$50.23
Open:
$50.61
24h Volume:
1.49M
Relative Volume:
0.53
Market Cap:
$9.38B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-20.37
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-4.36%
1M Performance:
+7.23%
6M Performance:
+33.19%
1Y Performance:
+97.19%
1-Day Range:
$48.84
$50.73
1-Week Range:
$48.03
$51.00
52-Week Range:
$21.72
$51.86
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
49.08 | 9.37B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales - Yahoo Finance
BridgeBio Pharma (BBIO) president sells shares worth $871k - Investing.com
BridgeBio Pharma: Betting Big On Rare Disease Catalysts (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Duquesne Family Office Q2 Trades: Warner Bros. and Nu Holdings Added, BridgeBio and Teck Resources Ditched - AInvest
Druckenmiller's Duquesne adds Warner Bros., exits BridgeBio among Q2 trades (WBD:NASDAQ) - Seeking Alpha
Wedbush initiates coverage on BridgeBio with Outperform rating and $25 price target. - AInvest
Is it too late to sell BridgeBio Pharma Inc.Weekly Trading Summary & AI Optimized Trade Strategies - Newser
How to interpret RSI for BridgeBio Pharma Inc. stockJuly 2025 Breakouts & Detailed Earnings Play Strategies - Newser
Reversal indicators forming on BridgeBio Pharma Inc. stockMarket Movers & Consistent Growth Equity Picks - Newser
Why BridgeBio Pharma (BBIO) Is Poised to Deliver Strong Returns as It Near Breakeven and Gains Analyst Momentum - AInvest
BridgeBio Pharma Expected to Breakeven Within Two Years with 69% Annual Growth Rate - AInvest
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Is Expected To Breakeven In The Near Future - Yahoo Finance
Measuring BridgeBio Pharma Inc.’s beta against major indices2025 Market Outlook & Weekly High Momentum Picks - Newser
Should you wait for a breakout in BridgeBio Pharma Inc.Weekly Trend Summary & Long Hold Capital Preservation Tips - Newser
Comparing BridgeBio Pharma Inc. in custom built stock radarsProfit Target & Risk Managed Investment Strategies - Newser
How to manage a losing position in BridgeBio Pharma Inc.Weekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
Analyzing recovery setups for BridgeBio Pharma Inc. investors2025 Growth vs Value & AI Powered Market Entry Strategies - Newser
Day 7 of Gains Streak for BridgeBio Pharma Stock with 15% Return (vs. 87% YTD) [8/15/2025] - Trefis
What makes BridgeBio Pharma Inc. stock price move sharplyMarket Volume Summary & Fast Exit/Entry Strategy Plans - Newser
Vanguard Group Inc. Cuts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Purchased by US Bancorp DE - Defense World
BridgeBio Pharma (BBIO) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Momentum Screeners Rank BridgeBio Pharma Inc. in Top 5 TodayMarket Performance Recap & Advanced Technical Analysis Signals - beatles.ru
Finance Watch: OrbiMed’s New $1.86bn Fund Offers Financial Alternatives In Tough Market - insights.citeline.com
BridgeBio Pharma stock hits 52-week high at 49.84 USD - Investing.com
Bridgebio Pharma Insider Sold Shares Worth $13,912,443, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma Inc. Stock Approaches Key Moving Average [Market Performance Recap]Free Technical Analysis for Trade Confirmation - 선데이타임즈
BridgeBio Pharma director Homcy sells $13.9m in stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma director Homcy sells $13.9m in stock - Investing.com
BridgeBio Pharma: Director Charles J Homcy sells 2.09M shares for $91.5M - AInvest
How BridgeBio Pharma Inc. stock performs during market volatilityReal-Time Trade Breakout Scanner - kangso.co.kr
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance
Mizuho Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Insider Sold Shares Worth $3,666,949, According to a Recent SEC Filing - 富途牛牛
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
BridgeBio Pharma Inc. Stock Approaches Key Moving AverageAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Bank of America Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Reports Strong Q2 2025 Results - The Globe and Mail
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Australia
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):